Finasteride Sexual Side Effects: Rates, Causes, and What to Do

Sexual adverse effects are the most commonly reported category of finasteride side effects. They are real, documented in double-blind clinical trials, acknowledged in the FDA label, and occur in a minority of men. This page explains exactly what the trial data shows, the proposed mechanisms, and what to do if you experience them.

Clinical Trial Rates

Sexual Side Effect	Finasteride 1 mg	Placebo	Drug-attributable excess
Decreased libido	1.8%	1.3%	0.5%
Erectile dysfunction	1.3%	0.7%	0.6%
Ejaculation disorder (decreased volume)	0.8%	0.4%	0.4%
Any of the above (combined)	~3.8%	~2.1%	~1.7%

Decreased Libido

Decreased libido (reduced sex drive) is the most commonly reported sexual adverse effect. The proposed mechanism involves DHT’s role as a precursor to neuroactive steroids — particularly allopregnanolone — that modulate central nervous system androgen and GABA-A receptor signaling involved in sexual motivation. Peripheral effects on genital tissue may also contribute. In most clinical trial participants who experienced decreased libido, it resolved after stopping finasteride.

Erectile Dysfunction

Erectile dysfunction on finasteride 1 mg occurred in 1.3% of trial participants vs. 0.7% on placebo — a drug-attributable excess of 0.6%. The mechanism may involve reduced DHT’s effects on smooth muscle in the corpus cavernosum, reduced nitric oxide synthase activity, or neurosteroid pathway disruption. Importantly, pre-existing risk factors for ED (cardiovascular disease, hypertension, diabetes, age) are the dominant predictors of ED in the general population; these confounders are important to consider when attributing ED to finasteride in a real-world clinical context.

Ejaculation Disorders

Decreased ejaculate volume is the most common ejaculatory adverse effect — caused by reduced secretory function of the prostate and seminal vesicles (both DHT-dependent). This is physiologically distinct from other ejaculatory disorders and is directly linked to the drug’s pharmacological mechanism. It typically resolves on stopping finasteride. Reduced ejaculate volume does not equate to impaired fertility, though finasteride can affect semen parameters at higher doses; this is relevant for men trying to conceive.

The Nocebo Effect

A key confounding factor in real-world reports of finasteride sexual side effects is the nocebo effect — side effects caused by the expectation of harm. Mondaini et al. (2007) demonstrated that men who were explicitly warned about finasteride’s sexual side effects before starting it reported 3× more erectile dysfunction than men who were not warned (44% vs. 15% in an open-label trial). This does not mean sexual side effects are all nocebo — the double-blind trial data proves a real pharmacological effect. But it means real-world reported rates are inflated by this psychological component.

What To Do If You Experience Sexual Side Effects

1. Report to your prescribing physician promptly. Do not self-manage or stop without medical guidance
2. Track objectively. Use validated tools (IIEF — International Index of Erectile Function) to document changes from baseline
3. Evaluate other causes. Rule out cardiovascular disease, thyroid dysfunction, hypogonadism, depression, and medication interactions — all independent causes of sexual dysfunction
4. If persistent after stopping: Seek evaluation for PFS (full PFS guide) and report to FDA MedWatch

See the full side effects hub for complete coverage of all finasteride adverse effects.